Etanercept
Etanercept is a biologic medication produced by Merck Group. It is a fusion protein that acts as a tumor necrosis factor (TNF) inhibitor.
Lab products found in correlation
5 protocols using etanercept
Etanercept modulates cardiomyocyte hypertrophy
Isolating and Culturing Synoviocytes for Cytokine and Therapeutic Response Analysis
For cytokine stimulation, cells were treated with or without various concentrations (1, 10, and 100 ng/mL) of PDGF-BB (BioLegend; San Diego, CA, USA), TGF-β (BioLegend), or TNF-α (BioLegend) for 2 days, as per our approved experimental design. The role of therapeutic drugs was determined by treating cells stimulated with cytokines with 10, 25, or 50 μg/mL etanercept (Pfizer, NY, USA) or 7.5 μM or 15 μM palbociclib (Sigma–Aldrich), or a combination of 25 μg/mL etanercept and 7.5 μM palbociclib for 1 day, as per our experimental design. These doses of cytokines and inhibitors were selected based on the findings of previous studies (20 (link)–23 (link)). WST-8 assays were performed to assess cell proliferation by using the Cell Counting Kit-8 (CK04; Dojindo).
Cardioprotective Effects of Etanercept
Etanercept and Metrnl Modulate Immune Responses
Innate Immune Modulation Protocol
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!